ストックスクリーナーアプリを入手
65.63
2.13%
1.37
前日終値:
$64.26
開ける：
$65.7
24時間の取引高:
6.33M
Relative Volume:
1.23
時価総額：
$204.58B
収益：
$51.21B
当期純損益:
$6.50B
株価収益率:
33.15
EPS:
1.98
ネットキャッシュフロー:
$6.76B
1週間 パフォーマンス:
+3.80%
1か月 パフォーマンス:
-15.12%
6か月 パフォーマンス:
-16.71%
1年 パフォーマンス:
+3.18%
1日の値動き範囲:
$65.56
$66.45
1週間の範囲:
$62.75
$66.45
52週間の値動き範囲:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
名前
Astrazeneca PLC
セクター
電話
44 20 3749 5000
住所
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| AZN | 65.63 | 204.58B | 51.21B | 6.50B | 6.76B | 1.98 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca PLC (AZN) 最新ニュース
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca (AZN) and Amgen (AMGN) Submit New Asthma Drug Application - GuruFocus.com
AstraZeneca’s Andexxa May Continue Dangling In Accelerated Approval After Mixed Advisory Panel - News & Insights
AstraZeneca rises Thursday, outperforms market - MarketWatch
AstraZeneca, Merck Add Patent to Campaign on Lynparza Copies (1) - Bloomberg Law
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns - Benzinga
CEO & Executive Director of AstraZeneca Picks Up 9.9% More Stock - Simply Wall St
We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative - Yahoo Finance
Primecap Management Co. CA Trims Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now - The Motley Fool
AstraZeneca upgraded to Neutral from Sell at UBS - Yahoo Finance
AstraZeneca Talks Up US Growth as China Problems Fester - MSN
astrazeneca non-executive director buys company shares By Investing.com - Investing.com Nigeria
How AstraZeneca Ruling Could Change Dosage Patent Claims - Law360
Claim Spotter: AstraZeneca calls in Fieldfisher over HQ fire - The Lawyer
AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch
As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - MSN
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call Transcript - MSN
AstraZeneca, United Utilities, AFC Energy: What brokers said today, - Proactive Investors UK
AstraZeneca raised to neutral at UBS despite China headwinds - MSN
AstraZeneca stock raised to neutral at UBS (AZN:NASDAQ) - Seeking Alpha
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
AstraZeneca Says Current, Former Executives Involved in China Probe - MSN
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Jennison Associates LLC - MarketBeat
Howe & Rusling Inc. Decreases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time - Pharmaceutical Technology
AstraZeneca Loses Lone Bear as UBS Upgrades After China-Led Rout - Bloomberg
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Boosted by Pathstone Holdings LLC - MarketBeat
AstraZeneca upgraded by leading investment bank, but challenges remainhere's why - Proactive Investors USA
AstraZeneca: UBS is no longer a seller - Marketscreener.com
AstraZeneca hits out at NICE block to breast cancer drug - Proactive Investors UK
AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview - News & Insights
AstraZeneca PLC ADR rises Tuesday, still underperforms market - MarketWatch
AstraZeneca rises Tuesday, outperforms market - MarketWatch
Trump-induced Pharma fears shouldn't be long-lived - Marketscreener.com
AstraZeneca (AZN) Faces Legal Scrutiny Amid Chinese Investigatio - GuruFocus.com
New Millennium Group LLC Sells 28,749 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC - Yahoo Finance
Prospera Financial Services Inc Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Leerink Partnrs Cuts Earnings Estimates for AstraZeneca - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Sumitomo Mitsui Trust Group Inc. - MarketBeat
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC - Pharmaceutical Technology
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca - Korea Economic Daily
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLCAZN - PR Newswire
Stocks in news: Waaree Energies, GMR Infra, AstraZeneca, Indus Towers, Ashoka Buildcon & ITI - Business Today
AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback - Citeline News & Insights
AstraZeneca PLC ADR rises Monday, still underperforms market - MarketWatch
AstraZeneca falls Monday, underperforms market - MarketWatch
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership - Pharmaceutical Technology
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Astrazeneca PLC (AZN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):